Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 14 | 2024 | 1520 | 5.590 |
Why?
|
Leukemia, Myeloid, Acute | 30 | 2024 | 3524 | 3.540 |
Why?
|
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 5 | 2024 | 407 | 2.270 |
Why?
|
Antibodies, Bispecific | 3 | 2023 | 164 | 1.700 |
Why?
|
Asparaginase | 2 | 2024 | 236 | 1.590 |
Why?
|
Myeloproliferative Disorders | 5 | 2024 | 606 | 1.480 |
Why?
|
Hematologic Neoplasms | 9 | 2024 | 1832 | 1.380 |
Why?
|
Hematopoietic Stem Cell Transplantation | 13 | 2022 | 5445 | 1.270 |
Why?
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 2022 | 689 | 1.140 |
Why?
|
fms-Like Tyrosine Kinase 3 | 5 | 2023 | 491 | 1.080 |
Why?
|
Aniline Compounds | 2 | 2021 | 986 | 1.000 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 12 | 2024 | 11524 | 0.890 |
Why?
|
Antineoplastic Agents | 7 | 2024 | 13691 | 0.870 |
Why?
|
Anthracyclines | 2 | 2023 | 288 | 0.860 |
Why?
|
Myelodysplastic Syndromes | 5 | 2024 | 1352 | 0.840 |
Why?
|
Mycoses | 2 | 2022 | 376 | 0.780 |
Why?
|
Lymphoma, T-Cell | 1 | 2024 | 299 | 0.780 |
Why?
|
Cytarabine | 3 | 2021 | 692 | 0.750 |
Why?
|
Hypertriglyceridemia | 1 | 2023 | 295 | 0.730 |
Why?
|
Osteonecrosis | 1 | 2022 | 227 | 0.720 |
Why?
|
Epstein-Barr Virus Infections | 3 | 2015 | 570 | 0.710 |
Why?
|
Antifungal Agents | 2 | 2022 | 729 | 0.600 |
Why?
|
Music Therapy | 3 | 2023 | 102 | 0.590 |
Why?
|
Recombinant Fusion Proteins | 3 | 2024 | 3772 | 0.580 |
Why?
|
Antibiotics, Antineoplastic | 2 | 2023 | 690 | 0.580 |
Why?
|
Staurosporine | 1 | 2017 | 251 | 0.570 |
Why?
|
Nuclear Proteins | 6 | 2023 | 5854 | 0.560 |
Why?
|
Protein Kinase Inhibitors | 6 | 2023 | 5532 | 0.560 |
Why?
|
Neoplasm, Residual | 2 | 2018 | 973 | 0.550 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2018 | 255 | 0.550 |
Why?
|
Lymphoproliferative Disorders | 3 | 2015 | 524 | 0.540 |
Why?
|
Lymphoma | 2 | 2023 | 1875 | 0.540 |
Why?
|
Daunorubicin | 1 | 2016 | 158 | 0.540 |
Why?
|
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2017 | 222 | 0.530 |
Why?
|
Leukemic Infiltration | 1 | 2015 | 48 | 0.520 |
Why?
|
Triazoles | 1 | 2021 | 904 | 0.520 |
Why?
|
Pyrazines | 1 | 2021 | 1230 | 0.510 |
Why?
|
Skin Neoplasms | 3 | 2024 | 5691 | 0.490 |
Why?
|
Mutation | 13 | 2023 | 29777 | 0.440 |
Why?
|
Quinolines | 1 | 2018 | 732 | 0.430 |
Why?
|
Nitriles | 1 | 2018 | 953 | 0.430 |
Why?
|
Orthopedics | 1 | 2022 | 904 | 0.430 |
Why?
|
Remission Induction | 6 | 2023 | 2384 | 0.430 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2023 | 2074 | 0.420 |
Why?
|
Humans | 88 | 2024 | 743811 | 0.400 |
Why?
|
Young Adult | 19 | 2024 | 56392 | 0.400 |
Why?
|
Burkitt Lymphoma | 1 | 2013 | 326 | 0.400 |
Why?
|
Sulfonamides | 4 | 2024 | 1938 | 0.370 |
Why?
|
Disease-Free Survival | 6 | 2023 | 6895 | 0.360 |
Why?
|
Aged | 26 | 2024 | 163178 | 0.350 |
Why?
|
Recurrence | 7 | 2024 | 8337 | 0.330 |
Why?
|
Salvage Therapy | 1 | 2015 | 1275 | 0.330 |
Why?
|
Immunotherapy, Adoptive | 1 | 2017 | 1271 | 0.320 |
Why?
|
T-Lymphocytes | 4 | 2024 | 10179 | 0.320 |
Why?
|
Protein-Tyrosine Kinases | 1 | 2018 | 2453 | 0.320 |
Why?
|
Leukemia | 3 | 2024 | 1509 | 0.320 |
Why?
|
Receptors, Antigen, T-Cell | 1 | 2017 | 2540 | 0.320 |
Why?
|
Prognosis | 15 | 2023 | 29052 | 0.310 |
Why?
|
Transplantation, Homologous | 5 | 2022 | 4777 | 0.310 |
Why?
|
Cyclophosphamide | 4 | 2020 | 2241 | 0.310 |
Why?
|
Retrospective Studies | 16 | 2023 | 77410 | 0.300 |
Why?
|
Monocytes | 2 | 2015 | 2593 | 0.300 |
Why?
|
Child | 14 | 2024 | 77637 | 0.300 |
Why?
|
Organ Transplantation | 2 | 2015 | 1140 | 0.300 |
Why?
|
Interleukin-3 Receptor alpha Subunit | 2 | 2024 | 39 | 0.300 |
Why?
|
Transplantation Conditioning | 3 | 2022 | 1599 | 0.290 |
Why?
|
Vincristine | 3 | 2020 | 1039 | 0.280 |
Why?
|
Cytogenetics | 2 | 2017 | 203 | 0.280 |
Why?
|
Adolescent | 16 | 2024 | 85729 | 0.280 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2015 | 1596 | 0.270 |
Why?
|
Hodgkin Disease | 1 | 2013 | 1415 | 0.270 |
Why?
|
Adult | 26 | 2024 | 213889 | 0.260 |
Why?
|
Dendritic Cells | 4 | 2024 | 2720 | 0.250 |
Why?
|
Middle Aged | 27 | 2022 | 213241 | 0.240 |
Why?
|
Risk Assessment | 2 | 2023 | 23327 | 0.240 |
Why?
|
High-Throughput Nucleotide Sequencing | 1 | 2016 | 3591 | 0.230 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 1 | 2013 | 1377 | 0.230 |
Why?
|
Polymerase Chain Reaction | 4 | 2017 | 6170 | 0.230 |
Why?
|
Philadelphia Chromosome | 1 | 2022 | 112 | 0.210 |
Why?
|
Bone Marrow | 3 | 2023 | 2951 | 0.210 |
Why?
|
Doxorubicin | 3 | 2020 | 2234 | 0.210 |
Why?
|
Core Binding Factors | 2 | 2022 | 31 | 0.210 |
Why?
|
Isocitrate Dehydrogenase | 3 | 2023 | 871 | 0.200 |
Why?
|
Skin | 1 | 2015 | 4372 | 0.200 |
Why?
|
Dexamethasone | 3 | 2020 | 1950 | 0.200 |
Why?
|
Disseminated Intravascular Coagulation | 1 | 2022 | 188 | 0.200 |
Why?
|
Transplants | 2 | 2015 | 209 | 0.190 |
Why?
|
Disease Progression | 1 | 2017 | 13273 | 0.190 |
Why?
|
Sarcoma, Myeloid | 1 | 2021 | 59 | 0.190 |
Why?
|
Male | 28 | 2024 | 349776 | 0.190 |
Why?
|
Thrombocythemia, Essential | 1 | 2021 | 105 | 0.190 |
Why?
|
Polycythemia Vera | 1 | 2021 | 164 | 0.180 |
Why?
|
Fusion Proteins, bcr-abl | 1 | 2022 | 434 | 0.180 |
Why?
|
Herpesvirus 4, Human | 3 | 2014 | 1041 | 0.180 |
Why?
|
Treatment Outcome | 11 | 2022 | 63042 | 0.180 |
Why?
|
Leukemia, Neutrophilic, Chronic | 1 | 2019 | 12 | 0.180 |
Why?
|
Music | 1 | 2023 | 262 | 0.170 |
Why?
|
Female | 28 | 2023 | 380020 | 0.170 |
Why?
|
Typhus, Endemic Flea-Borne | 1 | 2018 | 4 | 0.170 |
Why?
|
Hepatitis B | 1 | 2024 | 693 | 0.160 |
Why?
|
DNA Methylation | 3 | 2017 | 4286 | 0.150 |
Why?
|
Azepines | 1 | 2019 | 334 | 0.150 |
Why?
|
Azacitidine | 3 | 2024 | 347 | 0.150 |
Why?
|
Antimetabolites, Antineoplastic | 1 | 2021 | 640 | 0.150 |
Why?
|
Eosinophilia | 1 | 2022 | 541 | 0.150 |
Why?
|
Neurotoxicity Syndromes | 1 | 2021 | 290 | 0.150 |
Why?
|
Clone Cells | 1 | 2020 | 1692 | 0.140 |
Why?
|
Acute Disease | 2 | 2024 | 7150 | 0.140 |
Why?
|
Cardiovascular Diseases | 1 | 2021 | 15142 | 0.130 |
Why?
|
Arabinonucleosides | 1 | 2015 | 35 | 0.130 |
Why?
|
WT1 Proteins | 1 | 2016 | 178 | 0.130 |
Why?
|
Age Factors | 3 | 2020 | 18355 | 0.130 |
Why?
|
Viremia | 3 | 2008 | 736 | 0.130 |
Why?
|
Neoplasms | 5 | 2024 | 21675 | 0.130 |
Why?
|
Postoperative Complications | 2 | 2015 | 15281 | 0.130 |
Why?
|
Antigens, CD19 | 1 | 2017 | 380 | 0.120 |
Why?
|
Drug Therapy | 1 | 2018 | 496 | 0.120 |
Why?
|
Methotrexate | 1 | 2021 | 1726 | 0.120 |
Why?
|
Incidence | 2 | 2023 | 20948 | 0.120 |
Why?
|
Microspheres | 1 | 2017 | 777 | 0.120 |
Why?
|
Etoposide | 1 | 2015 | 641 | 0.120 |
Why?
|
Exanthema | 1 | 2018 | 501 | 0.120 |
Why?
|
Donor Selection | 1 | 2015 | 201 | 0.110 |
Why?
|
In Situ Hybridization, Fluorescence | 2 | 2022 | 2649 | 0.110 |
Why?
|
Chromosomes, Human, Pair 11 | 1 | 2013 | 417 | 0.110 |
Why?
|
Genes, myc | 1 | 2013 | 399 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2023 | 9239 | 0.100 |
Why?
|
Overweight | 1 | 2023 | 2371 | 0.100 |
Why?
|
DNA Mutational Analysis | 2 | 2019 | 4183 | 0.100 |
Why?
|
Chromosomes, Human, Pair 8 | 1 | 2013 | 460 | 0.100 |
Why?
|
Lymphoma, Mantle-Cell | 1 | 2014 | 233 | 0.100 |
Why?
|
Epigenomics | 1 | 2017 | 903 | 0.100 |
Why?
|
DNA, Neoplasm | 1 | 2017 | 1758 | 0.100 |
Why?
|
Drug Approval | 1 | 2017 | 742 | 0.100 |
Why?
|
Flow Cytometry | 3 | 2017 | 5973 | 0.100 |
Why?
|
Ventricular Function, Left | 1 | 2023 | 3660 | 0.090 |
Why?
|
Headache | 1 | 2018 | 1224 | 0.090 |
Why?
|
Stroke Volume | 1 | 2023 | 5002 | 0.090 |
Why?
|
Proportional Hazards Models | 2 | 2022 | 12354 | 0.090 |
Why?
|
Sarcoma | 1 | 2021 | 1898 | 0.090 |
Why?
|
Geriatric Assessment | 1 | 2017 | 1372 | 0.090 |
Why?
|
Aged, 80 and over | 6 | 2022 | 57744 | 0.090 |
Why?
|
Fatigue | 1 | 2017 | 1530 | 0.090 |
Why?
|
Hospitals | 1 | 2023 | 3953 | 0.090 |
Why?
|
Bone Marrow Transplantation | 1 | 2017 | 2764 | 0.090 |
Why?
|
Sequence Deletion | 1 | 2013 | 1524 | 0.080 |
Why?
|
Gene Dosage | 1 | 2013 | 1252 | 0.080 |
Why?
|
Quantitative Trait Loci | 1 | 2017 | 2018 | 0.080 |
Why?
|
Immunophenotyping | 1 | 2013 | 1880 | 0.080 |
Why?
|
Survival Rate | 2 | 2021 | 12786 | 0.080 |
Why?
|
Janus Kinase 2 | 2 | 2021 | 528 | 0.080 |
Why?
|
Pyrimidines | 1 | 2019 | 2945 | 0.080 |
Why?
|
Disease Management | 1 | 2018 | 2459 | 0.080 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2017 | 2942 | 0.070 |
Why?
|
Drug Resistance, Neoplasm | 2 | 2022 | 5170 | 0.070 |
Why?
|
Epigenesis, Genetic | 2 | 2022 | 3645 | 0.070 |
Why?
|
Combined Modality Therapy | 2 | 2015 | 8637 | 0.070 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2727 | 0.070 |
Why?
|
Survival Analysis | 2 | 2016 | 10251 | 0.070 |
Why?
|
Self Report | 1 | 2017 | 3550 | 0.070 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2016 | 2944 | 0.070 |
Why?
|
Body Mass Index | 1 | 2023 | 12718 | 0.070 |
Why?
|
Genetic Association Studies | 1 | 2015 | 2703 | 0.070 |
Why?
|
Models, Genetic | 1 | 2016 | 3492 | 0.070 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10940 | 0.070 |
Why?
|
Risk Factors | 7 | 2019 | 72252 | 0.060 |
Why?
|
HLA Antigens | 1 | 2011 | 1382 | 0.060 |
Why?
|
HIV Infections | 4 | 2024 | 16715 | 0.060 |
Why?
|
Parental Consent | 1 | 2005 | 62 | 0.060 |
Why?
|
Education, Medical | 1 | 2017 | 1722 | 0.060 |
Why?
|
Receptor Protein-Tyrosine Kinases | 2 | 2023 | 1660 | 0.060 |
Why?
|
Survivors | 1 | 2015 | 2291 | 0.060 |
Why?
|
Host-Pathogen Interactions | 1 | 2013 | 1479 | 0.060 |
Why?
|
Clinical Trials as Topic | 1 | 2020 | 7908 | 0.060 |
Why?
|
Sex Factors | 1 | 2018 | 10394 | 0.060 |
Why?
|
Anxiety | 3 | 2023 | 4288 | 0.060 |
Why?
|
Physician-Patient Relations | 1 | 2017 | 3229 | 0.060 |
Why?
|
Interferon-alpha | 1 | 2008 | 895 | 0.060 |
Why?
|
Receptors, Chemokine | 1 | 2006 | 670 | 0.060 |
Why?
|
Comorbidity | 1 | 2017 | 10380 | 0.060 |
Why?
|
Attitude of Health Personnel | 1 | 2017 | 3839 | 0.060 |
Why?
|
Pilot Projects | 3 | 2023 | 8316 | 0.050 |
Why?
|
Palliative Care | 1 | 2017 | 3490 | 0.050 |
Why?
|
Interferon Type I | 1 | 2006 | 541 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39001 | 0.050 |
Why?
|
Bilirubin | 1 | 2024 | 425 | 0.050 |
Why?
|
Blast Crisis | 1 | 2022 | 103 | 0.050 |
Why?
|
Lymph Nodes | 1 | 2013 | 3476 | 0.050 |
Why?
|
Cytokines | 2 | 2006 | 7324 | 0.050 |
Why?
|
Receptor, Platelet-Derived Growth Factor alpha | 1 | 2023 | 379 | 0.050 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2015 | 4477 | 0.050 |
Why?
|
Predictive Value of Tests | 1 | 2017 | 15067 | 0.050 |
Why?
|
Dysarthria | 1 | 2021 | 57 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2018 | 9944 | 0.050 |
Why?
|
Internship and Residency | 1 | 2021 | 5787 | 0.050 |
Why?
|
Obesity | 1 | 2023 | 12744 | 0.050 |
Why?
|
DNA | 1 | 2014 | 7295 | 0.050 |
Why?
|
Ohio | 1 | 2021 | 337 | 0.050 |
Why?
|
Polymorphism, Genetic | 1 | 2011 | 4326 | 0.050 |
Why?
|
Idarubicin | 1 | 2019 | 62 | 0.050 |
Why?
|
Diagnosis, Differential | 3 | 2021 | 12954 | 0.050 |
Why?
|
Diplopia | 1 | 2021 | 200 | 0.040 |
Why?
|
Viral Vaccines | 1 | 2005 | 636 | 0.040 |
Why?
|
Interleukin-2 | 1 | 2006 | 1904 | 0.040 |
Why?
|
HIV-1 | 2 | 2008 | 6939 | 0.040 |
Why?
|
Molecular Biology | 1 | 2023 | 595 | 0.040 |
Why?
|
Diagnostic Imaging | 1 | 2013 | 3503 | 0.040 |
Why?
|
Papillomaviridae | 1 | 2005 | 1119 | 0.040 |
Why?
|
Papillomavirus Vaccines | 1 | 2005 | 491 | 0.040 |
Why?
|
Confusion | 1 | 2021 | 275 | 0.040 |
Why?
|
Rickettsia typhi | 1 | 2018 | 5 | 0.040 |
Why?
|
Aging | 1 | 2017 | 8655 | 0.040 |
Why?
|
Physicians | 1 | 2017 | 4569 | 0.040 |
Why?
|
Disease Vectors | 1 | 2018 | 60 | 0.040 |
Why?
|
Accreditation | 1 | 2021 | 452 | 0.040 |
Why?
|
Cell Count | 1 | 2022 | 1855 | 0.040 |
Why?
|
Mouth Mucosa | 1 | 2021 | 432 | 0.040 |
Why?
|
Muscle Weakness | 1 | 2021 | 413 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 847 | 0.040 |
Why?
|
Transaminases | 1 | 2018 | 200 | 0.040 |
Why?
|
Cohort Studies | 6 | 2019 | 40545 | 0.040 |
Why?
|
Blood Cell Count | 1 | 2018 | 403 | 0.040 |
Why?
|
Texas | 1 | 2018 | 390 | 0.040 |
Why?
|
Stress, Psychological | 2 | 2023 | 4245 | 0.040 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 1 | 2024 | 1434 | 0.040 |
Why?
|
Doxycycline | 1 | 2018 | 326 | 0.040 |
Why?
|
Pregnancy | 1 | 2018 | 29140 | 0.040 |
Why?
|
Curriculum | 2 | 2021 | 3603 | 0.030 |
Why?
|
Time Factors | 2 | 2017 | 40038 | 0.030 |
Why?
|
Cytogenetic Analysis | 1 | 2015 | 294 | 0.030 |
Why?
|
Myeloablative Agonists | 1 | 2015 | 218 | 0.030 |
Why?
|
Genetic Predisposition to Disease | 1 | 2016 | 17439 | 0.030 |
Why?
|
Qualitative Research | 1 | 2023 | 2682 | 0.030 |
Why?
|
Cross-Sectional Studies | 1 | 2015 | 25032 | 0.030 |
Why?
|
Minority Groups | 1 | 2021 | 1222 | 0.030 |
Why?
|
CD4-Positive T-Lymphocytes | 1 | 2006 | 4386 | 0.030 |
Why?
|
Bone Marrow Cells | 1 | 2021 | 2509 | 0.030 |
Why?
|
Graft vs Host Disease | 2 | 2017 | 2958 | 0.030 |
Why?
|
Multiple Myeloma | 1 | 2011 | 5185 | 0.030 |
Why?
|
Papillomavirus Infections | 1 | 2005 | 1587 | 0.030 |
Why?
|
Binding Sites | 1 | 2022 | 6111 | 0.030 |
Why?
|
Infant | 1 | 2015 | 35122 | 0.030 |
Why?
|
Pandemics | 2 | 2023 | 8385 | 0.030 |
Why?
|
Child, Preschool | 1 | 2015 | 40964 | 0.030 |
Why?
|
Demography | 1 | 2017 | 1653 | 0.030 |
Why?
|
Travel | 1 | 2018 | 788 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2017 | 12243 | 0.030 |
Why?
|
Kaplan-Meier Estimate | 2 | 2014 | 6539 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2021 | 5078 | 0.030 |
Why?
|
Parents | 1 | 2005 | 3403 | 0.030 |
Why?
|
Antibodies, Monoclonal, Murine-Derived | 1 | 2014 | 693 | 0.020 |
Why?
|
Fever | 1 | 2018 | 1616 | 0.020 |
Why?
|
Repressor Proteins | 1 | 2022 | 3024 | 0.020 |
Why?
|
Cell Cycle Proteins | 1 | 2022 | 3463 | 0.020 |
Why?
|
Chromatin | 1 | 2022 | 2931 | 0.020 |
Why?
|
Hemorrhage | 1 | 2022 | 3458 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2019 | 4204 | 0.020 |
Why?
|
Medical Oncology | 1 | 2021 | 2267 | 0.020 |
Why?
|
Prednisone | 1 | 2014 | 1574 | 0.020 |
Why?
|
Proto-Oncogene Proteins | 1 | 2022 | 4552 | 0.020 |
Why?
|
Transplantation, Autologous | 1 | 2014 | 2123 | 0.020 |
Why?
|
Signal Transduction | 2 | 2023 | 23398 | 0.020 |
Why?
|
Education, Medical, Graduate | 1 | 2021 | 2291 | 0.020 |
Why?
|
Cells, Cultured | 2 | 2019 | 19232 | 0.020 |
Why?
|
Transplantation Immunology | 1 | 2011 | 546 | 0.020 |
Why?
|
Hematopoietic Stem Cells | 1 | 2021 | 3389 | 0.020 |
Why?
|
Massachusetts | 1 | 2021 | 8660 | 0.020 |
Why?
|
Reproducibility of Results | 2 | 2017 | 19894 | 0.020 |
Why?
|
Receptors, CCR7 | 1 | 2006 | 108 | 0.020 |
Why?
|
Influenza A Virus, H3N2 Subtype | 1 | 2006 | 90 | 0.020 |
Why?
|
Tetanus Toxoid | 1 | 2006 | 193 | 0.020 |
Why?
|
HIV Long-Term Survivors | 1 | 2006 | 126 | 0.020 |
Why?
|
Tissue Donors | 1 | 2015 | 2241 | 0.020 |
Why?
|
Ribavirin | 1 | 2008 | 394 | 0.020 |
Why?
|
Herpesvirus 3, Human | 1 | 2006 | 204 | 0.020 |
Why?
|
Gene Expression Regulation, Viral | 1 | 2006 | 442 | 0.020 |
Why?
|
Cell Differentiation | 1 | 2021 | 11478 | 0.010 |
Why?
|
Genomics | 1 | 2019 | 5714 | 0.010 |
Why?
|
Depression | 1 | 2023 | 7760 | 0.010 |
Why?
|
Gene Expression Profiling | 1 | 2019 | 9440 | 0.010 |
Why?
|
Influenza A Virus, H1N1 Subtype | 1 | 2006 | 459 | 0.010 |
Why?
|
Adenoviridae | 1 | 2006 | 1100 | 0.010 |
Why?
|
Education | 1 | 2005 | 543 | 0.010 |
Why?
|
Cytomegalovirus | 1 | 2006 | 733 | 0.010 |
Why?
|
United States | 2 | 2021 | 69859 | 0.010 |
Why?
|
Quality of Life | 1 | 2023 | 12788 | 0.010 |
Why?
|
Leukocytes, Mononuclear | 1 | 2008 | 1836 | 0.010 |
Why?
|
Focus Groups | 1 | 2005 | 1320 | 0.010 |
Why?
|
Graft Survival | 1 | 2011 | 3734 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2018 | 7172 | 0.010 |
Why?
|
Animals | 2 | 2023 | 168660 | 0.010 |
Why?
|
HIV | 1 | 2006 | 1604 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2006 | 4931 | 0.010 |
Why?
|
Interviews as Topic | 1 | 2005 | 2538 | 0.010 |
Why?
|
Prospective Studies | 1 | 2023 | 53250 | 0.010 |
Why?
|
Interferon-gamma | 1 | 2006 | 3205 | 0.010 |
Why?
|
Recombinant Proteins | 1 | 2008 | 6620 | 0.010 |
Why?
|
Graft Rejection | 1 | 2011 | 4398 | 0.010 |
Why?
|
Hepatitis C | 1 | 2008 | 1591 | 0.010 |
Why?
|
Anti-Retroviral Agents | 1 | 2006 | 1714 | 0.010 |
Why?
|
Mice | 1 | 2023 | 81154 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2006 | 4422 | 0.010 |
Why?
|
Antiviral Agents | 1 | 2006 | 2984 | 0.010 |
Why?
|
Vaccination | 1 | 2005 | 3275 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2011 | 21733 | 0.010 |
Why?
|